Intravenous immunoglobulin-based immunotherapy: An arsenal of possibilities for patients and science

Immunotherapy

Volumn 1, Issue 6, 2009, Pages 995-1014

  Kotlan, Beatrix ^a   Stroncek, David F ^b   Marincola, Francesco M ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Autoimmune disease; Cancer; Ganglioside; Immunomodulatory effect; Immunotherapy; Intravenous immunoglobulin; Miscarriage; Natural antibody; Recurrent; Tumor associated antigen

Indexed keywords

CARIMUNE NF; CORTICOSTEROID; GAMMA VENIN; GAMMAGARD SD; GAMMAVENIN P; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTRATECT; KIOVIG; RITUXIMAB; SUBCUVIA; UNCLASSIFIED DRUG; VIGAM; VIVAGLOBULIN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTHRITIS; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD PRESSURE; CANCER IMMUNOTHERAPY; CHEST TIGHTNESS; CHILL; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEVER; FLUSHING; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOTHERAPY; MALAISE; MELANOMA; MONITORING; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; NEUTROPENIA; PATHOGENESIS; PNEUMONIA; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT INDICATION; VOMITING;

ABORTION, HABITUAL; ANIMALS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; PREGNANCY; TRANSLATIONAL RESEARCH;

EID: 77953433224     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.67     Document Type: Review

References (236)

1. Marincola FM: Translational medicine: a two way road. J. Transl. Med. 1(1), 1 (2003).
2. Wolff-Eisner A: Handbuch der Serumtherapie und Experimentellen Therapie: Ein Handbuch für Klinik und Praxis. München JF. Lehmanns Verlag, Germany (1910).
3. McKhann CF, Green AA, Coady H: Factors influencing the effectiveness of placental extract in the prevention and modification of measles. J. Pediatr. 6, 603-614 (1935).
4. Bruton OC: Agammaglobulinemia. Pediatrics 52, 722-728 (1952).
5. Martin MH: Recognition of the hypogammaglobulinaemia syndrome. In: Hypogammaglobulinaemia in the United Kingdom. MRC Working Party on Hypogammaglobulinaemia, Her Majesty's Stationery Office, London, UK 1-3 (1971).
6. Sapir T, Blank M, Shoenfeld Y: Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer and recurrent pregnancy loss. Ann. NY Acad. Sci. 1051, 743-778 (2005). ■■ Comprehensive, quite detailed, but well-summarized view about the immunomodulatory effects of intravenous immunoglobulins (IVIG) as a suitable treatment possibility for autoimmune diseases, cancer and recurrent pregnancy loss.
7. Sapir T, Shoenfeld Y: Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin. Rev. Allergy Immunol. 29, 185-199 (2005).
8. Shoenfeld Y, Katz U: IVIG therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38, 123-137 (2005). ■ Authors present their experiences with a large cohort of patients using IVIG therapy in autoimmunity and related disorders. (Pubitemid 40872737)
9. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N: Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double blind, placebo-controlled study. Brain 124, 145-153 (2001).
10. Comi G, Nemni R, Amadio S, Galardi G, Leocani L: Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immunemediated neuropathies. Mult. Scler. 3, 93-97 (1997).
11. Nimmerjahn F, Ravetch JV: The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204, 11-15 (2007).
12. Stricker RB, Winger EE: Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin. Am. J. Reprod. Immunol. 54, 390-396 (2005).
13. Kotlan B, Padanyi A, Batorfi J et al.: Alloimmune and autoimmune background in recurrent pregnancy loss - successful immunotherapy by intravenous immunoglobulin. Am. J. Reprod. Immunol. 55, 331-340 (2006). ■ Authors are reasoning why a careful patient selection with defining alloimmune and autoimmune background in recurrent pregnancy loss, seems to be important for a successful IVIG immunotherapy.
14. Clark DA: Immunological factors in pregnancy wastage: fact or fiction. Am. J. Reprod. Immunol. 59, 277-300 (2008).
15. Fishman P, Bar-Yehuda S, Shoenfeld Y: IVIG to prevent tumor metastases. Int. J. Oncol. 21, 875-880 (2002).
16. Sapir Tal, Shoenfeld Y: Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin. Rev. Allergy Immunol. 29, 307-310 (2005).
17. Cohn EJ: The history of plasma fractionation. In: Company in Advances in Military Medicine, Vol 1. Andrus EC, Bronk DW, Carden GA, (Eds). Little, Brown and Company, Boston, MA, USA 364-443 (1948).
18. Barandun S, Morell A, Skvaril F: Clinical experiences with immunoglobulin for intravenous use. In: Immunglobulins: Characteristics and Uses of Intravenous Preparations. Alving BM, Finlayson JS (Eds). US Department of Health and Human Services, Washington DC, USA 31-35 (1979).
19. Barandun S, Kistler P, Jeunet F et al.: Intravenous administration of human gammaglobulin. Vox Sang. 7, 157-174 (1962).
20. Barandun S, Isliker H: Development of immunoglobulin preparations for intravenous use. Vox Sang. 51, 157-160 (1986). (Pubitemid 16046159)
21. Eibl MM: History of immunoglobulin replacement. Immunol. Allergy Clin. N. Am. 28, 737-764 (2008). ■■ Detailed review about the history of immunoglobulin replacement therapy.
22. Silvestris F, Cafforio P, Dammacco F: Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin. Exp. Immunol. 97, 19-25 (1994).
23. Hemming VG: Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin. Diag. Lab. Immunol. 8, 859-863 (2001). ■ Describes the new era of infectious disease prevention introducing IVIG and also some new aspects of usage.
24. Samster's Immunologic Diseases. Austen F, Frank MM, Atkinson JP, Cantor H (Eds). Lippincott Williams and Wilkins, PA, USA 1191-1192 (2001).
25. Busse PJ, Razvi S, Cunningham-Rundles C: Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 109, 1001-1004 (2002).
26. Adib M, Ragimbeau J, Avrameas S, Ternynck T: IgG autoantibody activity in normal mouse serum is controlled by IgM. J. Immunol. 145, 3807-3813 (1990).
27. Seite JF, Shoenfeld Y, Youinou P, Hillion S: What is the contents of the magic draft IVIG? Autoimmunity Rev, 7, 435-439 (2008).
28. Orange JS, Hossny EM, Weiler CR et al.: Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin. Immunol. 117, S525-S553 (2006).
29. Zandman-Goddard G, Shoenfeld Y: Novel approaches to therapy for systemic lupus erythematosus. Eur. J. Int. Med. 11, 130-134 (2000).
30. Zandman-Goddard G, Levy Y, Shoenfeld Y: Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 29, 219-228 (2005).
31. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin. Adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29, 173-184 (2005).
32. Katz U, Shoenfeld Y: Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14, 802-808 (2005). (Pubitemid 41597614)
33. Katz U, Achiron A, Sherer Y, Shoenfeld Y: Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmunity Rev. 6, 257-259 (2007). (Pubitemid 46274552)
34. Nydegger UE, Mohacsi PJ, Escher R et al.: Clinical use of intravenous Immunglobulins. Vox Sang. 78, 191-195 (2000).
35. Toubi E, Etzioni A: Intravenous immunoglobulin in immunodeficiency states. Clin. Rev. Allergy Immunol. 29, 167-172 (2005).
36. Shoenfeld Y, Amital H, Ferrone S, Kennedy RC: Anti-idiotypes and their application under autoimmune, neoplastic and infectious conditions. Int. Arch. Allergy Immunol. 105, 211-223 (1994).
37. Omwandho CO, Gruessner SE, Roberts TK, Tinneberg HR: Intravenous immunoglobulin (IVIG) modes of action in the clinical management of recurrent pregnancy loss (PRL) and selected autoimmune disorders. Clin. Chem. Lab. Med. 42, 359-370 (2004).
38. Blank M, Anafi L, Zandman-Goddard G etal.: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): throphoblast invasiveness and APS animal model. Int. Immunol. 19, 857-865 (2006)
39. Le Pottier L, Bendaoud B, Dueymes M et al.: BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J. Clin. Immunol. 27, 257-265 (2007).
40. Kammula US, Marincola FM: Cancer immunotherapy: is there a real progress at last? BioDrugs 11, 249-260 (1999).
41. Wang E, Panelli MC, Monsurro V, Marincola FM: A global approach to tumor immunology. Cell. Mol. Immunol. 1, 256-265 (2004).
42. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24, 335-342 (2003).
43. Sherer Y, Wu R, Krause I et al.: Cytokine levels in various intravenous immunoglobulin (IVIG) preparations. Hum. Antibodies 10, 51-53 (2001).
44. Clynes R: IVIG therapy: interfering with interferon-γ. Immunity 26, 4-6 (2007).
45. Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A: Long term safety of IVIG therapy in multiple sclerosis: 10 years experience. Autimmunity 39, 513-517 (2006). (Pubitemid 44575084)
46. Prins C, Gelfand EW, French LE: Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm. Venereol. 87, 206-218 (2007). ■■ Comprehensive review with the most important characteristics of IVIG and very important novel aspects about its therapeutic usage in dermatology.
47. Sewell WAC, Jolles S: Immunomodulatory action of intravenous immunoglobulin. Immunology 107, 387-393 (2002).
48. Jolles S, Sewell WAC, Misbah SA: Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 142, 1-11 (2005).
49. WHO/IUIS notice. Appropriate uses of human immunoglobulin in clinical practice. Clin. Exp. Immunol. 52, 417-422 (1983).
50. Imbach P, d'Apuzzo V, Hirt A: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228-1231 (1981).
51. Nugent DJ: IVIG in the treatment of children with acute and chronic idiopathic thrombocytopenic purpura and the autoimmune cytopenias. Clin. Rev. Allergy Immunol. 10, 59-71 (1992).
52. Buckley RH, Schiff RI: The use of intravenous immunoglobulin in immunodeficiency diseases. N. Engl. J. Med. 325, 110-117 (1991).
53. Burns JC, Capparelli EV, Brown JA et al.: Intravenous γ-globulin treatment and retreatment in Kawasaki disease. US/Canada Kawasaki Syndrome Study Group. Pediatr. Infect. Dis. J. 17, 1144-1148 (1998).
54. Fillit H: Intravenous immunoglobulins for Alzheimer's disease. Lancet Neurol. 3, 704 (2004).
55. Solomon B: Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr. Opin. Mol. Ther. 9, 79-85 (2007).
56. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD: Intravenous immunoglobulins (IVIG) in the treatment of autoimmune diseases. Clin. Exp. Immunol. 86, 192-198 (1991).
57. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345, 747-755 (2001).
58. Pyne D, Ehrenstein M, Morris V: The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 41, 367-374 (2002). (Pubitemid 34546006)
59. Cocito D, Ciaramitaro P, Isoardo G et al.: Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol. 249, 719-722 (2002). (Pubitemid 34651754)
60. Luke PP, Scantlebury VP, Jordan MI et al.: IVIG rescue therapy in renal transplantation. Transplant. Proc. 33, 1093-1094 (2001).
61. Orbach H, Shoenfeld Y: Vaccination in infection and autoimmunity: myth and reality. Autoimmun. Rev. 6, 261-266 (2007).
62. Orbach H, Tishler M, Shoenfeld Y: Intravenous immunoglobulin and a kidney - a two-edged sword. Semin. Arthritis Rheum. 34, 593-601 (2004
63. Gurmin V, Mediwake R, Fernando M, Whittaker S, Rustin MH, Beynon HL: Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br. J. Dermatol. 147, 554-557 (2002).
64. Taguchi Y, Takashima S, Yoshima S, Dougu N, Inoue H, Tanaka K: Psoriasis improved by intravenous immunoglobulin therapy. Intern. Med. 45, 879-880 (2006).
65. Jolles S, Hughes J: Use of IVIG in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis and pretibial. myxedema. Int. Immunopharmacol. 6, 579-591 (2005).
66. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R.: Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 57, 406-409 (2008). (Pubitemid 351304803)
67. Kauffman CL, Aria N, Toivhi E et al.: A Phase I study evaluating the safety, phamacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriais. J. Invest. Dermatol. 123, 1037-1044. (2004.)
68. Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN: Successful intravenous immunoglobulin therapy in cases of parvovirus B19-associated chronique fatigue syndrome. Clin. Infect. Dis. 36, E100-E106 (2003).
69. Vollner-Conna U, Hickie I, Hadzi-Pavlovic D et al.: Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am. J. Med. 103, 38-43 (1997).
70. Debré M, Bonnet MC, Fridman WH et al.: Infusion of Fc-γ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993). (Pubitemid 23305497)
71. Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001). (Pubitemid 32097072)
72. Kurlander RJ: Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G.J. Clin. Invest. 66, 773-781 (1980).
73. Braun-Moscovici Y, Furst DE: Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr. Opin. Rheumatol. 15, 237-245 (2003).
74. Levy Y, Sherer Y, Ahmed K et al.: Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat. Immun. 16, 207-214 (1998).
75. Andermariam B, Bussel J: New therapies for immune thrombocytopenic purpura, Curr. Opin. Hematol. 4, 427-431 (2007).
76. Rossi F, Sultan Y, Kazatchkine MD: Anti-idiotypes against autoantibodies and alloantibodies to VIILC (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin. Exp. Immunol. 74, 311-316 (1988)
77. Pul R, Stangel M: Using immunoglobulins in muscular disease treatment. Expert Opin. Biol. Ther. 8, 1143-1150 (2008).
78. Blank M, Anafi L, Zandman-Goddard G et al.: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19, 857-865 (2007)
79. Reinhold D, Perlov E, Schrecke K, Kekow J, Brune T, Sailer M: Increased blood plasma concentrations of TGF-β isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis. J. Neuroimmunol. 152, 191-194 (2004). (Pubitemid 38829717)
80. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735 (1994)
81. Hartung HP: Advances int he understanding of the mechanism of action of IVIG. J. Neurol. 255, 3-6 (2008).
82. Viard I, Wehrli P, Bullani R et al.: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998). (Pubitemid 28483679)
83. Prasad NK, Papoff G, Zeuner A et al.: Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 161(7), 3781-3790 (1998).
84. Shoenfeld Y, Fishman P: γ-globulin inhibits tumor spread in mice. Int. Immunol. 11, 1247-1252 (1999).
85. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139, 5-19 (1994).
86. Mocellin S, Marincola FM, Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J. Leuk. Biol. 78, 1-10 (2005).
87. Asadullah K, Volk HD: Role of IL-10 in psoriasis. In: Interleukin-10. Marincola FM (Ed.). Eurekah, Chapter 8B (2004).
88. + T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann. N. Y. Acad. Sci. 1051, 506-514 (2005).
89. Szereday L, Spath P, Szekeres-Bartho J: Natural killer cell activity and cytokine production after in vitro immunoglobulin treatment of lymphocytes derived from pregnant women with or without risk for spontaneous abortion. Am. J. Reprod. Immunol. 42, 282-287 (1999).
90. Ibanez C, Montoro-Ronsano JB: Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr. Pharm. Biotechnol. A, 239-247 (2003).
91. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N: Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95, 2032-2037 (2002). (Pubitemid 35222185)
92. Senzaki H, Masutani S, Kobayashi J et al.: Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104, 860-863 (2001). (Pubitemid 32778033)
93. Furukawa S, Matsubara T, Jujoh K et al.: Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin. Immunol. Immunopathol. 48, 247-251 (1988)
94. Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S: An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm. Res. 53, 253-256 (2004).
95. Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P: IVIG therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127, 2649-2656 (2004). (Pubitemid 39627374)
96. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB: Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β-chain. Proc. Natl Acad. Sci. USA 89, 3325-3329 (1992).
97. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM: The dual role of IL-10. Trends Immunol. 24, 36-43 (2003).
98. Shoenfeld Y, Levy Y, Fishman P: Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. Isr. Med. Assoc. J. 3, 698-699 (2001).
99. Merimsky O, Meller I, Bar-Yehuda S, Shoenfeld Y, Fishman P: A possible role for IVIG treatment of soft tissue sarcoma: a clinical case and an experimental model. Int. J. Oncol. 20, 839-843 (2002).
100. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Roloti B: Prophylaxis against infections with low dose intravenous immunoglobulin (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81, 121-126 (1996).
101. Bayry J, Lacroix-Desmazes S, Carbonneil C etal: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101, 758-765 (2003)
102. Bussel JB, Graziano JN, Kimberly RP et al.: Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity and mechanism of effect. Blood 77, 1884-1893 (1991).
103. Frank MM, Basta M, Fries LF: The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 62, S82-S86 (1992).
104. Marchalonis JJ, Kaymaz H, Dedeoglu F et al.: Human autoantibodies reactive with synthetic autoantigens from T cell receptor β chain. Proc. Natl Acad. Sci. USA 89, 3325-3329 (1992).
105. Jordan SC, Vo A, Bunnapradist S et al.: Intravenous immunoglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76, 631-636 (2003).
106. Winston DJ, Ho WG, Rasmussen LE et al.: Use of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28, 187-196 (2001).
107. Andermariam B, Bussel J: New therapies for immune thrombocytopenic purpura. Curr. Opin. Hematol. 4, 427-431 (2007).
108. Shoenfeld Y, Blank M, Abu-Shakra M et al.: The mosaic of autoimmunity: prediction, autoantibodies and therapy in autoimmune diseases - 2008. Isr. Med. Assoc. J. 10, 13-19 (2008).
109. Michael D, Grando SA: Novel mechanisms for therapeutic action of IVIG in autoimmune blistering dermatoses. Curr. Dir. Autoimmun. 10, 333-343 (2008).
110. Fishman P, Merimsky O, Shoenfeld Y: Autoimmunity and cancer-beneficial relationships: a new concept for the production of human monoclonal antibodies. Int. J. Oncol. 10, 901-904 (1997)
111. Shoenfeld Y, Gershwin EM: Autoantibodies, autoimmunity and cancer. In: Cancer and Autoimmunity. Elsevier Science, Amsterdam, The Netherlands 1-450 (2000).
112. Swissa M, Cohen Y, Shoenfeld Y: Autoantibodies in the sera of patients with lymphoma. Leuk. Lymphoma 7, 117-122 (1992).
113. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL: Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J. 8(5), 384-394 (2002).
114. Taylor DD, Gercel-Taylor C: Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? Oncol. Rep. 5, 1519-1524 (1998).
115. Fishman P, Azizi E, Shoenfeld Y et al.: Vitiligo autoantibodies are effective against melanoma. Cancer 72, 2365-2367 (1993). (Pubitemid 23299599)
116. Baharav E, Merimsky O, Altomonte M et al.: Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high molecular weight melanoma-associated antigen. Melanoma Res. 5, 337-343 (1995).
117. Schachter J, Katz U, Mahrer A et al.: Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann. N. Y. Acad. Sci. 1110, 305-314 (2007) ■■ Presents important pioneering data about the efficacy and safety of IVIG administration in patients with metastatic melanoma.
118. Merimsky O, Meller I, Inbar M, Bar-Yehuda S, Shoenfeld Y, Fishman P: A possible role for IVIG in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int. J. Oncol. 20, 839-843 (2002).
119. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 335, 1772-1779 (2006).
120. Buskila D, Abu-Shakra M, Shoenfeld Y: Anti-idiotypic therapy in autoimmunity. In: Cancer and Autoimmunity. Shoenfeld Y, Gershwin ME (Eds). Elsevier Science, Amsterdam, The Netherlands 365-377 (2000).
121. Foon KA, John WJ, Chakraborty M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembrionic antigen. J. Clin. Oncol. 17, 2889-2895 (1999).
122. Besa EC, Klumpe D: Prophylactic immune globulin in chronic lymphocyte leukemia. N Engl. J. Med. 326, 139 (1992).
123. Carmeli Y, Mevorach D, Kaminski N, Raz E: Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 73, 2859-2861 (1994). (Pubitemid 24166277)
124. Mocellin S, Rossi CR, Lise M, Marincola FM: Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol. Immuother. 51, 583-595 (2002).
125. Mocellin S, Wang E, Marincola FM: Cytokine and immune response in the tumor microenvironment. J. Immunother. 24, 392-407 (2001). (Pubitemid 33029909)
126. Mocellin S, Panelli M, Wang E et al.: IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 5, 621-630 (2004). (Pubitemid 40045300)
127. Panelli MC, Marincola FM: Role of IL-10 in Cancer. In: Interleukin-10. Marincola FM (Ed.). Eurekah, Chapter 9 (2004).
128. Noronha EJ, Wang X, Deasi SA, Zhang D, Willers J, Soldano F: Active specific immunotherapy of malignant diseases-breaking tolerance to self-antigens with tumor associated antigen mimics. In: Cancer and Autoimmunity. Shoenfeld Y, Gershwin ME (Eds). Elsevier Science, Amsterdam, The Netherlands 379-395 (2000).
129. Wang E, Worschech A, Marincola FM: The immunologic constant of rejection. Trends Immunol. 29, 256-262 (2008).
130. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371, 771-783 (2008).
131. Keilholz U, Weber J, Finke JH et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunotherapy 25, 97-138 (2002). (Pubitemid 34260764)
132. Caspi RR: Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8, 970-976 (2008)
133. Pelegrin M, Gros L, Dreja H, Piechaczyk M: Monoclonal antibody-based genetic immunotherapy. Curr. Gene Ther. A, 347-356 (2004).
134. Alfonso M, Diaz A, Hernandez AM et al.: An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168, 2523-2529 (2002). (Pubitemid 34171859)
135. Quan WD, Dean GE, Spears L et al.: Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: a Phase I/II trial of I-Mel-2 plus SAF-m. J. Clin. Oncol. 15, 2103-2110 (1997).
136. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. 2, 679-686 (1996).
137. Mittelman A, Chen ZJ, Kageshita T et al.: Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma- associated antigen monoclonal antibodies. J. Clin. Invest. 86, 2136-2144 (1990)
138. Chapman PB, Wu D, Rgupathi G et al.: Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10, 4717-4723 (2004).
139. Chapman PB, Williams L, Salibi N, Hwu WJ, Known SE, Livingston PO: A Phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22, 2904-2909 (2004).
140. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM: Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev. Vaccines. 2, 89-95 (2003).
141. Gocht A, Rutter G, Kniep R: Changed expression of 9-O-acetyl GD3 (CDw60) in benign and atypical proliferative lesions and carcinomas of the human breast. Histochem. Cell. Biol. 110, 217-229 (1998)
142. Popa J, Pons A Mariller C et al.: Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology 17, 367-373 (2007).
143. Engelmann K, Finn OJ: Tumor antigens as modulators of the tumor microenvironment. In: Innate and Adaptive Immunity in the Tumor Microenvironment. Yefenof E (Ed.). Springer, NY, USA 91-119 (2008).
144. Dickie MN, Ragupathi G, Liu NX et al.: Immunogenicity of a gucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 5, 2773-2779 (1999).
145. Terryberry J W, Shoenfeld Y, Sherer Y et al.: Detection of antibodies to gangliosides and glycolipids in various immunoglobulin (IVIG) preparations. Immunol. Invest. 29, 337-347 (2000).
146. Foreman AL, Water JV, Gougeon ML, Gershwin ME: B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (IgV) gene usage. Autoimmun. Rev. 6, 387-401 (2007).
147. Marincola FM: The future of immunotherapy: a call for comparative immunology. Immunotherapy 1, 1-3 (2009)
148. Wang E, Albini A, Stroncek DF, Marincola FM: A new take on comparative immunology: relevance to immunotherapy. Immunotherapy 3, 355-360 (2009).
149. Vollmers PH, Brandlein S: Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Human Antibodies 11, 131-142 (2002).
150. Vollmers PH, Brandlein S: Natural human immunoglobulins in cancer immunotherapy. Immunotherapy 1, 241-248 (2009). ■■ Describes very interestingly the highly important aspects and role of natural human immunoglobulins in cancer immunotherapy.
151. Abu-Shakra M, Shoenfeld: Natural hidden autoantibodies. Isr. Med. Assoc. J. 9, 748-749 (2007).
152. Kazathkine MD, Kaveri SV: Immunomodulation of autoimmun and inflammatory diseases with intravenous immune globulin. N. Engl. Med. 345, 747-755 (2001).
153. Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisas JO, Notkins AL: The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 1, 51-61 (2007). (Pubitemid 46506009)
154. Sherer Y, Levy Y, Shoenfeld Y: IVIG in autoimmunity and cancer-efficacy versus safety. Expert Opin. Drug Saf. 1, 153-158 (2002).
155. Teeling JL, Jansen-Hendriks T, Kuijpers TW et al.: Therapeutic efficacy of IVIG preparations depends on the IgG dimers: studies in experimental immune thrombocytopenia. Blood 98, 1095-1099 (2001).
156. Kaveri S, Vassilev T, Hurez V et al.: Antibodies to a conserved region of HLA class molecules, capable of modulating CD8 T cell mediated finction, are present in pooled normal immunoglonulin for therapeutic usage. J. Clin. Invest. 97, 865-869 (1996).
157. Svenson M, Hansen MB, Ross C et al.: Antibody to GM-CSF is a dominant anti-cytokine activityin human IgG preparations. Blood 91, 2054-2061 (1996).
158. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB: Human autoantibodies reactive with synthetic autoantigens from cell receptor β chain. Proc. Natl Acad. Sci. USA 89, 3325-3329 (1992).
159. Rossi F, Kazatchkine MD: Anti-idiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 143, 4104-4109 (1989) (Pubitemid 20012601)
160. Wang X, Desai S, Noronha EJ, Mittelman A, Ferrone S: The anti-idiotypic approach to active specific immunotherapy of malignant melanoma. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Shoenfeld Y, Kennedy RC, Ferone S (Eds). Elsevier Science, Amsterdam, The Netherlands 523-536 (1997).
161. Lobo PI, Schlegel KH, Spencer CE et al.: Naturally occuring IgM anti-leukocyte autoantibodies (IgM-ALA) inhibit T cell activation and chemotaxis. J. Immunol. 180, 1780-1791 (2008).
162. Giggi T, Bauer R, garofalo T et al.: Autoantibodies against ganglioside GM3 represents a portion of antilymphocytic antibodies in AIDS patients. Scand. J. Immunol. 40, 77-82 (1991).
163. Brandlein S, Lorenz J, Ruoff N et al.: Human mononclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum. Antibodies 11, 107-119 (2002). (Pubitemid 36470163)
164. Coronella-Wood JA, Hersh EM: Naturally occuring B-cell responses to breast cancer. Cancer Immunol. Immunother. 52, 715-738 (2003).
165. Vollmers HP, Brandlein S: Death by stress: natural IgM-induced apoptosis. Methods Find. Exp. Clin. Pharmacol. 27, 185-191 (2005).
166. Toubi E, Shoenfeld Y: Protective autoimmunity in cancer. Oncology Reports 17, 245-251 (2007).
167. Wang E, Selleri S, Sabatino M et al.: Spontaneous and treatment-induced cancer rejection in humans. Expert Opin. Biol. Ther. 8, 337-349 (2008).
168. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371, 771-783 (2008).
169. Waldman TA: Anti-Tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: 25 year personal odyssey. J. Clin. Immunol. 27, 1-18 (2007)
170. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses int he autologous host. Proc. Natl Acad. Sci. USA 92, 11810-11813 (1995).
171. Kotlan B, Gruel N, Zafrani B et al.: Immunoglobulin variable regions usage by B-lymphocates infiltrating a human breast medullary carcinoma. Immunol. Lett. 65, 143-151, (1999)
172. Kotlan B, Simsa P, Teillaud JL et al.: Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J. Immunol. 175, 2278-2285 (2005). (Pubitemid 41113835)
173. Wang Y, Ylera F, Boston M et al.: Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res. Treat. 104, 129-144 (2007).
174. Glassy MC, McKnight M, Kotlan B, Glassy EF, Koda K: Cocktails of human anti cancer antibodies show a synergistic effect in nude mouse tumor xenografts. Human Antibodies 16, 87-98 (2007) (Pubitemid 351359898)
175. Willis SN, Mallozzi SS, Rodig SJ et al.: The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J. Immunol. 182, 3310-3317 (2009).
176. Vollmers PH, Dammrich J, Ribbert H et al.: Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76, 550-558 (1995).
177. Mouthon L, Nobrega A, Nicolas N et al.: Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc. Natl Acad. Sci. USA 92, 3839-3843 (1995).
178. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139, 5-18 (1994).
179. Nachbaur D, Herold M, Gachter A, Niederwieser D: Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology 94, 279-283 (1998). (Pubitemid 28267487)
180. Vassilev TL, Bineva IL, Dietrich G et al.: Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J. Autoimmunity 8, 405-413 (1995).
181. 2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 90, 212-218 (1997).
182. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006). (Pubitemid 44201145)
183. Blank M, Analfi L, Zandman-Goddard G et al.: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19, 857-865 (2007).
184. Ravindranath MH, Ravindranath RMH: Human antiganglioside autoantibodies. In: Autoantibodies. Shoenfeld Y, Gershwin ME, Meroni PL (Eds). Elsevier Science, Amsterdam, The Netherlands 277-283 (2007).
185. + B cells. Cell. Mol. Life Sci. 53, 750-758 (1997).
186. Willison HJ: Ganglisode autoantibodies. In: Autoantibodies. Shoenfeld Y, Gershwin ME, Meroni PL (Eds). Elsevier Science, Amsterdam, The Netherlands 611-618 (2007).
187. Mehta AS, Long RE, Comunale MA et al.: Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J. Virology 82, 1259-1270 (2008).
188. Hakomori S: Traveling for the glycosphingolipid path. Glycoconj. J. 17, 627-647 (2000).
189. Birkle S, Gao L, Zeng G, Yu RK.: Down-regulation of GD3 ganglioside and its O-acetylated derivative by stable transfection with antisense vector against GD3-synthase gene expression in hamster melanoma cells: effects on cellular growth, melanogenesis and dendricity. J. Neurochem. 74, 547-554 (2000). (Pubitemid 30053726)
190. Le Poole I C, Riker AI, Quevedo ME et al.: Interferon-γ reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am. J. Pathol. 160, 521-528 (2002).
191. Skov L, Chan LS, Fox DA et al.: Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratynocytes. Am. J. Pathol. 150, 675-683 (1997).
192. Ravindranath MH, Yesowitch P, Sumobay C, Morton DL: Glycoimmunomics of human cancer: current concepts and future perpectives. Future Oncol. 3, 201-214 (2007). ■■ Well-documented review that gives a perfect description about the previously rather neglected but highly important novel era of glycoantigens and lipoantigens and their relation to tumor immunology.
193. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63, 7995-8005 (2003). (Pubitemid 37466738)
194. Rauschert N, Brandlein S, Holzinger E, Hensel F, Muller-Hermelink HK, Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 88, 375-386 (2008).
195. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco) lipid metabolism. Cancer Res. 56, 5309-5318 (1996).
196. Sjoberg ER, Manzit AE, Khoo KH, Dell A, Varki A: Structural and immunological characterization of O-acetylated GD2. J.Biol. Chem. 267, 16200-16211 (1992).
197. Malisan F, Franchi L, Tomassini B et al.: Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J. Exp. Med. 196, 1535-1541 (2002).
198. Hakomori S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001).
199. Kotlan B, Glassy MC: Antibody phage display. Overview of a powerful technology that has quickly translated to the clinic. In: Methods in Molecular Biology. Aitken R (Ed.). Humana Press Inc., NY, USA 1-16 (2009).
200. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths A, Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597 (1991).
201. Osei A, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P: Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum. A3, 2722-2732 (2000).
202. Hoffmann M, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P: IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ line gene origin as in autoimmune thrombocytopenia. Clin. Exp. Immunol. 121, 37-46 (2000).
203. Mian S, Bradwell AR, Olson AJ: Structure, function and properties of antibody binding sites. J. Mol. Biol. 217, 133-151 (1991).
204. Ravindranath MH, Muthugounder S, Hannah MR, Morton DL: Significance of endogenous augmentation of antiganglioside IgM in cancer patients. Potential tool for early detection and management of cancer therapy. Ann. N. Y. Acad. Sci. 1107, 212-222 (2007).
205. Zhang W, Matsumoto-Takasaki, Kushada Y et al.: Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 2. Expression, purification and characterization of recombinant single chain antibodies. Biochemistry 46, 263-270 (2007).
206. Kotlan B, Simsa P, Foldi J et al.: Immunoglobulin repertoire of B lymphocytes infiltrating human breast medullary carcinomas. Human Antibodies 12, 113-121 (2003). (Pubitemid 38657147)
207. Simsa P, Teillaud JL, Stott I D, Toth J, Kotlan B: Immunoglobulin variable region gene usage of B lymphocytes in ductal breast carcinomas. Pathol. Oncol. Res. 11, 92-97 (2005).
208. Wang Y, Ylera F, Boston M et al.: Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res. Treat. 104, 129-144 (2007).
209. Nagorsen D, Monsurro V, Marincola F: Characterization of tumor-directed cellular immune responses in humans. In: Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response. Kaise HE, Nasir A (Eds). Springer Science and Business Media, NY, USA 157-167 (2008).
210. György B, Tóthfalusi L, Nagy G et al.: Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. Arthritis Res. Ther. 10, 1-12 (2008).
211. Buzas EI, Bence GY, Pásztoi M, Jelinek I, Falus A, Gabius HJ: Carbohydrate recognition systems in autoimmunity. Autoimmunity 39, 691-704 (2006).
212. Ravindranath MH: Glycoimmunomics of human cancer: relevance to monitoring biomarkers of early detection and therapeutic response. In: Clinical Applications of Immunomics. Falus A (Ed.). Springer Science and Business Media, NY, USA 225-267 (2008).
213. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y: Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin. Rev. Allergy Immunol. 29, 213-217 (2005). ■ Authors present a novel realistic possibility with their first experiences to prepare specifically enriched IVIG products with up-to-date techniques.
214. Wang J, Zhang B, Fang J et al.: Frontal affinity chromatography coupled to mass spectrometry: an effective method for Kd determination and screening of a-Gal derivatives binding to anti-Gal antibodies (IgG). J. Carbohy. Chem. 22, 347-376 (2003). (Pubitemid 37412122)
215. Clark DA, Coulam CV, Stricker RM: Is intravenous immunoglobulins (IVIG) efficacious in eraly pregnancy failure? A critical review and meta-analysis. J. Assist. Reprod. Genet. 23, 1-13 (2006).
216. Clark DA: Immunological factors in pregnancy wastage: fact or fiction. Am. J. Reprod. Immunol. 59, 277-300 (2008).
217. Clark DA: Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure? J. Assist. Reprod Genet. 20, 63-72 (2003).
218. Hutton B, Sharma R, Fergusson D et al.: Use of intravenous immunoglonulin treatment of miscarriage: a systemic review. BJOG 114, 134-142 (2007). (Pubitemid 46089441)
219. Coulam CB, Krya L, Stern JJ, Bustillo M: Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am. J. Reprod. Immunol. 34, 333-337 (1995).
220. Christiansen OB, Mathiesen O, Husth M et al.: Placebo controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum. Reprod. 10, 2690-2695 (1995).
221. Sticker RB, Steinleitner A, Bookoff CN et al.: Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. Fertil. Steril. 73, 536-540 (2000).
222. Coulab CB, Stephenson M, Stern JJ, Clark DA: Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am. J. Reprod. Immunol. 35, 352-359 (1996).
223. Christiansen OB: Intravenous immunoglobulin in the prevention of recurrent spontaneous abortion: the European experience. Am. J. Reprod. Immunol. 39, 77-81 (1998).
224. Scott JR: Immunotherapy for recurrent miscarriage. Cochrane Database Syst. Rev. 1, CD000112 (2003).
225. Branch DV, Peaceman AM, Druzin M et al.: A multi-center, placebo-controlled pilot study of intravenous immunoglobulin treatment of phospholipid syndrome during pregnancy. AmJ. Obstet. Gynecol. 182, 122-127 (2000).
226. Kotlan B, Fulop V, Padanyi A et al.: High partner antigen specific cytotoxic T lymphocyte precursor frequencies in women with unexplained recurrent spontaneous abortions. Hum. Reprod. 16, 1278-1285 (2001)
227. Padányi A, Horuzsko A, Gyodi E et al.: Humoral and cell mediated factors involved in the suppressive regulation induced by special blood derivatives and their clinical relevance. Transplant. Proc. 30, 1-5 (1998).
228. Kwak JY, Kwak FM, Ainbinder SW et al. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 35, 363-369 (1996)
229. Sherer Y, Levy Y, Shoenfeld Y: Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxf) 39, 421-426 (2000). (Pubitemid 30307329)
230. Rueda R, Tabsh K, Ladish S: Detection of complex gangliosides in human amniotic fluid. FEBS Lett. 328, 13-16 (1993). (Pubitemid 23234755)
231. The Electronic Medicines Compendium http://emc.medicines.org.uk
232. NHS Demand Management Programme for Immunoglobulin www.ivig.nhs.uk www.intravenousimmunoglobulin.org
233. Department of Health, Clinical Guidelines for Immunglobulin use www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-085235
234. www.gammaCan.com
235. US patent 5562902 (1996). (Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin)
236. US patent 6355244 (1998). (Methods and compositions for the treatment of psoriasis)